Host circulating biomarkers for immune-checkpoint inhibitors: single-agent and combinations

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Nixon NA, Blais N, Ernst S et al. Current landscape of immunotherapy in the treatment of solid tumours, with future opportunities and challenges. Curr. Oncol. 25(5), e373–e384 (2018).
  Medline CASGoogle Scholar
• 2. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 39(1), 1–10 (2013).
  MedlineGoogle Scholar
• 3. Prelaj A, Tay R, Ferrara R, Chaput N, Besse B, Califano R. Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer. Eur. J. Cancer 106, 144–159 (2019).
  Medline CASGoogle Scholar
• 4. Ji RR, Chasalow SD, Wang L et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol. Immunother. 61(7), 1019–1031 (2012).
  Medline CASGoogle Scholar
• 5. Kamphorst AO, Pillai RN, Yang S et al. Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. Proc. Natl Acad. Sci. USA 114(19), 4993–4998 (2017). • Demonstrates the association between expansion of CD8+Ki67+ cells with immune-checkpoint inhibitors (ICIs) single-agent outcomes.
  Medline CASGoogle Scholar
• 6. Ferrara R, Mezquita L, Auclin E, Chaput N, Besse B. Immunosenescence and immunecheckpoint inhibitors in non-small-cell lung cancer patients: does age really matter? Cancer Treat. Rev. 60, 60–68 (2017).
  Medline CASGoogle Scholar
• 7. Zuazo M, Arasanz H, Fernández-Hinojal G et al. Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy. EMBO Mol. Med. 11(7), e10293 (2019).
  MedlineGoogle Scholar
• 8. Jacquelot N, Roberti MP, Enot DP et al. Predictors of responses to immune checkpoint blockade in advanced melanoma. Nat. Commun. 8(1), 592 (2017).
  Medline CASGoogle Scholar
• 9. Kargl K, Zhu X, Zhang H et al. Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC. JCI Insight 4(24), e130850 (2019).
  MedlineGoogle Scholar
• 10. Bagley SJ, Kothari S, Aggarwal C et al. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. Lung Canc. 106, 1–7 (2017).
  MedlineGoogle Scholar
• 11. Suh KJ, Kim SH, Kim YJ et al. Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody. Cancer Immunol. Immunother. 67, 459e70 (2018).
  Google Scholar
• 12. Sacdalan DB, Lucero JA, Sacdalan DL. Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis. Onco. Targets Ther. 11, 955–965 (2018).
  MedlineGoogle Scholar
• 13. Ferrucci PF, Ascierto PA, Pigozzo J et al. Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. Ann. Oncol. 29(2), 524 (2018).
  Medline CASGoogle Scholar
• 14. Mezquita L, Arbour K, Auclin E et al. Derived neutrophil-to lymphocyte ratio (dNLR) change between baseline and cycle 2 is correlated with benefit during immune checkpoint inhibitors. Presented at: 20th World Conference on Lung Cancer. Barcelona, Spain (2019). •• Highlights the role of derived neutrophil-to-lymphocyte ratio (dNLR) monitoring, due to changes in dNRLR between first and second cycles that correlated with outcomes in a cohort of non-small-cell lung cancer (NSCLC) patients.
  Google Scholar
• 15. Mezquita L, Auclin E, Ferrara R et al. Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small-cell lung cancer. JAMA Oncol. 4(3), 351–357 (2018). •• Shows that high dNLR and lactate dehydrogenase were associated with reduced outcomes in NSCLC patients treated with ICI single-agent.
  MedlineGoogle Scholar
• 16. Sorich MJ, Rowland A, Karapetis CS, Hopkins AM. Evaluation of the lung immune prognostic index for prediction of survival and response in patients treated with atezolizumab for NSCLC: pooled analysis of clinical trials. J. Thorac. Oncol. 14(8), 1440–1446 (2019).
  Medline CASGoogle Scholar
• 17. Kazandjian D, Gong Y, Keegan P, Pazdur R, Blumenthal GM. Prognostic value of the lung immune prognostic index for patients treated for metastatic non-small-cell lung cancer. JAMA Oncol 5(10), 1481–1485 (2019).
  MedlineGoogle Scholar
• 18. Blanc-Durand F, Auclin E, Planchard D et al. Association of lung immune prognostic index (LIPI) with survival of first line immune checkpoint inhibitors single-agent or in combination with chemotherapy in untreated advanced NSCLC patients. Ann. Oncol. 30(11), xi1–xi11 (2019). •• Demonstrates the association between lung immune prognostic index and NSCLC patients treated with combination of ICI with chemotherapy in first-line setting.
  Google Scholar
• 19. Varga A, Bernard-Tessier A, Auclin E, Mezquita L, Baldini C, Planchard D et al. Applicability of the lung immune prognostic index (LIPI) in patients with metastatic solid tumors when treated with immune checkpoint inhibitors (ICI) in early clinical trials. Ann. Oncol. 30(Suppl.1), i2–i3 (2019).
  MedlineGoogle Scholar
• 20. Mezquita L, Martin P, Auclin E, Duchemann B, Cassard L, Planchard D et al. Circulating immature neutrophils, tumor-associated neutrophils and dNLR for identification of fast-progressors to immunotherapy in advanced NSCLC patients. Presented at: 20th World Conference on Lung Cancer. Barcelona, Spain (2019). •• Demonstrates the association between high dNLR and reduced outcomes in NSCLC patients treated with ICI single-agent.
  Google Scholar
• 21. Rosner S, Kwong E, Shoushtari AN et al. Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma. Cancer Med. 7, 690–697 (2018). • Demonstrates that high levels basophils and eosinophils correlate with increased survival in patients with malignant melanoma treated with ICI-ICI combination.
  Medline CASGoogle Scholar